These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32734828)

  • 41. In Silico Screening of Natural Flavonoids against 3-Chymotrypsin-like Protease of SARS-CoV-2 Using Machine Learning and Molecular Modeling.
    Cai L; Han F; Ji B; He X; Wang L; Niu T; Zhai J; Wang J
    Molecules; 2023 Dec; 28(24):. PubMed ID: 38138524
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Screening of natural compounds from Cyperus rotundus Linn against SARS-CoV-2 main protease (M
    Kumar SB; Krishna S; Pradeep S; Mathews DE; Pattabiraman R; Murahari M; Murthy TPK
    Comput Biol Med; 2021 Jul; 134():104524. PubMed ID: 34090015
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Potential of NO donor furoxan as SARS-CoV-2 main protease (M
    Al-Sehemi AG; Pannipara M; Parulekar RS; Patil O; Choudhari PB; Bhatia MS; Zubaidha PK; Tamboli Y
    J Biomol Struct Dyn; 2021 Sep; 39(15):5804-5818. PubMed ID: 32643550
    [TBL] [Abstract][Full Text] [Related]  

  • 44. On the search for COVID-19 therapeutics: identification of potential SARS-CoV-2 main protease inhibitors by virtual screening, pharmacophore modeling and molecular dynamics.
    Hassan A; Arafa RK
    J Biomol Struct Dyn; 2022 Oct; 40(17):7815-7828. PubMed ID: 33749545
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Structure-guided pharmacophore based virtual screening, docking, and molecular dynamics to discover repurposed drugs as novel inhibitors against endoribonuclease Nsp15 of SARS-CoV-2.
    Jha P; Saluja D; Chopra M
    J Biomol Struct Dyn; 2023 Jul; 41(11):5096-5106. PubMed ID: 35652904
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
    Ebrahimi M; Karami L; Alijanianzadeh M
    Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.
    Ancy I; Sivanandam M; Kumaradhas P
    J Biomol Struct Dyn; 2021 Sep; 39(15):5368-5375. PubMed ID: 32627689
    [TBL] [Abstract][Full Text] [Related]  

  • 48.
    Al-Sehemi AG; Parulekar RS; Pannipara M; P P MA; Zubaidha PK; Bhatia MS; Mohanta TK; Al-Harrasi A
    J Biomol Struct Dyn; 2023 Jan; 41(1):280-297. PubMed ID: 34809523
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Computational Study of Carbazole Alkaloids from Murraya koenigii as Potential SARS-CoV-2 Main Protease Inhibitors.
    Wadanambi PM; Jayathilaka N; Seneviratne KN
    Appl Biochem Biotechnol; 2023 Jan; 195(1):573-596. PubMed ID: 36107386
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target.
    Kundu D; Selvaraj C; Singh SK; Dubey VK
    J Biomol Struct Dyn; 2021 Jun; 39(9):3428-3434. PubMed ID: 32362243
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease.
    Forrestall KL; Burley DE; Cash MK; Pottie IR; Darvesh S
    Chem Biol Interact; 2021 Feb; 335():109348. PubMed ID: 33278462
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.
    Rai H; Barik A; Singh YP; Suresh A; Singh L; Singh G; Nayak UY; Dubey VK; Modi G
    Mol Divers; 2021 Aug; 25(3):1905-1927. PubMed ID: 33582935
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of potential antivirals against 3CLpro enzyme for the treatment of SARS-CoV-2: A multi-step virtual screening study.
    Kumar V; Kar S; De P; Roy K; Leszczynski J
    SAR QSAR Environ Res; 2022 May; 33(5):357-386. PubMed ID: 35380087
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.
    Abu-Saleh AAA; Awad IE; Yadav A; Poirier RA
    Phys Chem Chem Phys; 2020 Oct; 22(40):23099-23106. PubMed ID: 33025993
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Some Flavolignans as Potent Sars-Cov-2 Inhibitors
    Cetin A
    Curr Comput Aided Drug Des; 2022; 18(5):337-346. PubMed ID: 35975852
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Discovery of novel inhibitors of SARS-CoV-2 main protease.
    Zheng L; Chen Y; Bao J; He L; Dong S; Qi Y; Zhang JZH
    J Biomol Struct Dyn; 2022; 40(23):12526-12534. PubMed ID: 34472424
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In-silico pharmacophoric and molecular docking-based drug discovery against the Main Protease (Mpro) of SARS-CoV-2, a causative agent COVID-19.
    Haider Z; Subhani MM; Farooq MA; Ishaq M; Khalid M; Akram MN; Khan RSA; Niazi AK
    Pak J Pharm Sci; 2020 Nov; 33(6):2697-2705. PubMed ID: 33867348
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Screening of plant-based natural compounds as a potential COVID-19 main protease inhibitor: an
    Majumder R; Mandal M
    J Biomol Struct Dyn; 2022 Feb; 40(2):696-711. PubMed ID: 32897138
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
    Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
    Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking.
    Vázquez-Mendoza LH; Mendoza-Figueroa HL; García-Vázquez JB; Correa-Basurto J; García-Machorro J
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.